SCHEMBL4776525

SCHEMBL4776525

NCc1ccc(CNC(=O)c2ccc(NS(=O)(=O)CCc3cccc(Cl)c3Cl)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.47
PPARG P37231 1/20 0.47
EPHX2 P34913 3/20 0.43
NR1H4 Q96RI1 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CA2 P00918 4/20 0.42
CA1 P00915 3/20 0.42
MEN1 O00255 2/20 0.41
PKM P14618 2/20 0.41
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
HDAC1 Q13547 1/20 0.40
MCHR1 Q99705 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775200 0.92 L3MBTL1 (0.47) PPARAPPARGSMN1; SMN2NPSR1CA2
SCHEMBL4777500 0.91 EPHX2 (0.45) PPARAPPARGEPHX2NR1H4SMN1; SMN2
SCHEMBL4776480 0.91 PPARG (0.44) PPARAPPARGEPHX2NR1H4SMN1; SMN2
SCHEMBL4771091 0.89 EPHX2 (0.43) PPARAPPARGEPHX2NR1H4SMN1; SMN2
SCHEMBL4773551 0.89 PPARA (0.45) PPARAPPARGEPHX2NR1H4SMN1; SMN2
SCHEMBL4773543 0.88 EPHX2 (0.42) PPARAPPARGEPHX2NR1H4SMN1; SMN2
SCHEMBL4773523 0.87 EPHX2 (0.41) PPARAPPARGEPHX2NR1H4SMN1; SMN2
SCHEMBL5571827 0.85 ALDH1A1 (0.46) PPARAPPARGEPHX2NR1H4MEN1
SCHEMBL4776821 0.84 L3MBTL1 (0.43) EPHX2NR1H4CA2CA1MEN1
SCHEMBL4777461 0.84 TSHR (0.55) SMN1; SMN2MEN1KMT2AHDAC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 PPARA 2973/4885PPARG 2756/4885EPHX2 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.